Priority 4 from the Mesothelioma PSP
| In mesothelioma patients, what is the best second line treatment (i.e. what chemotherapy drugs should be used if a cancer has recurred following first line chemotherapy, usually with cisplatin and pemetrexed)? (JLA PSP Priority 4) | |
|---|---|
| Overall ranking | 4 |
| JLA question ID | 0025/4 |
| Explanatory note | Not available for this PSP |
| Evidence | No systematic reviews identified. Ongoing study - VIM - Vinorelbine in Mesothelioma |
| Health Research Classification System category | Cancer |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | After several courses of chemo with Carbo and Alimta I developed an allergic reaction to Alimta. What are my chemo options now? ~ Two months after this treatment the fluid was back and had his chest drained again. Why was he not offered further chemo? ~ role of second line chemotherapy includingg rechallenge with pemetrexed based chemotherapy ~ Dad was advised that he wouldn't be given any more chemo as it wouldn't work. On what basis is this deduced? Is this a funding issue? |
| Comparison | Drug |
| Submitted by | Patient ~ Bereaved ~ Health Professional ~ Carer |
| Outcomes to be measured | Response and survival |
| PSP information | |
|---|---|
| PSP unique ID | 0025 |
| PSP name | Mesothelioma |
| Total number of uncertainties identified by this PSP. | 53 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 16 December 2014 |